Application of monoclonal antibodies in multiple myeloma / 白血病·淋巴瘤

ABSTRACT

The survival time of multiple myeloma (MM) patients has been significantly prolonged due to improvements in therapy with the addition of novel agents, however, it's inevitable for some MM patients to have drug resistance. A certain number of MM patients can benefit from a new therapy, namely monoclonal antibodies (mAbs). This paper reviews the advances of mAbs in MM therapy.